Promontory Therapeutics, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2010-11-15
- Employees
- 11
- Market Cap
- -
- Website
- http://www.phosplatin.com
A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Biological: avelumab
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Promontory Therapeutics Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT03409458
- Locations
- ๐บ๐ธ
Colorado, Aurora, Colorado, United States
๐บ๐ธArizona, Phoenix, Arizona, United States
๐บ๐ธUniversity of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Promontory Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03288480
- Locations
- ๐บ๐ธ
Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States
๐บ๐ธMayo Clinic Cancer Center, Rochester, Minnesota, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Phase 2
Active, not recruiting
- Conditions
- Advanced Solid TumorsmCRPCProstatic NeoplasmsGenital Neoplasms, MaleNeoplasms by SiteCRPCMetastatic Castrate-resistant Prostate CancerPT-112Urogenital Neoplasms
- Interventions
- Drug: PT-112 Injection
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Promontory Therapeutics Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT02266745
- Locations
- ๐ซ๐ท
Bordeaux, Bordeaux, France
๐บ๐ธIndianapolis, Indianapolis, Indiana, United States
๐บ๐ธBoston, Boston, Massachusetts, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath